The present study examined a novel function of PRL-releasing peptide (PrRP) on the neuroendocrine. PrRP-immunoreactive nerve fibers and nerve terminals were located in the vicinity of the somatostatin (SOM)-neurons in the hypothalamic periventricular nucleus (PerVN). Immuno-electron microscopy revealed that PrRP-immunoreactive nerve terminals made synaptic contacts with nonimmunoreactive neuronal elements in the PerVN. Intracerebroventricular (icv) administration of PrRP induced immediate early gene, NGFI-A, in SOM-neurons in the PerVN. Doublelabeling in situ hybridization showed that some parts of SOMneurons in the PerVN expressed PrRP receptor messenger RNA. Therefore, some parts of SOM-neurons in the PerVN are considered to be directly innervated by PrRP via PrRP receptor. In addition to the above morphological characteristics, icv administration of PrRP decreased plasma GH levels. Such inhibitory effects of PrRP on the secretion of GH from the anterior pituitary were diminished by depletion or neutralization of SOM. From these findings it was strongly suggested that SOM-neurons respond to PrRP and secrete SOM into the portal vessels and thus inhibit GH secretion from the anterior pituitary. (Endocrinology 142: 3239 -3243, 2001) P RL-RELEASING peptide (PrRP) was isolated from bovine hypothalamus extract as a ligand of an orphan seven-transmembrane receptor (hGR3), which was predominantly expressed in the anterior pituitary. PrRP has two isoforms that consist of 20 or 31 amino acids with a carboxylterminal amidation motif, which are referred to as PrRP20 and PrRP31, respectively. Both PrRP showed potent PRL releasing activity from cultured anterior pituitary cells specifically (1). The iv administration of PrRP was shown to induce increased plasma PRL levels (2, 3).
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We previously reported the distribution of PrRP-immunoreactive neurons, fibers, and nerve terminals by immunocytochemistry (4, 5) . In that previous study, nerve-fibers with PrRP immunoreactivity were widely distributed in the forebrain and diencephalon. In the hypothalamus, many PrRP-fibers were predominantly found within the paraventricular nucleus (PVN) and periventricular nucleus (PerVN). On the other hand, Roland et al. (6) reported that PrRP receptor messenger RNA (mRNA) (rat's counterpart of hGR3, UHR-1) was detected within the PerVN and PVN. From these findings, we aimed to clarify whether PrRP plays significant roles such as stimulation of some neuropeptide synthesizing neurons in the PerVN and PVN other than the secretion of PRL from the anterior pituitary. In the present study, we focused on the effect of PrRP on somatostatin (SOM)-neurons in the hypothalamic PerVN.
Materials and Methods Animal
Male Wistar rats (8 weeks old) were purchased from Charles River Laboratories, Inc. (Yokohama, Japan). They were provided with food and water ad libitum, and kept under the conditions of controlled lighting and temperature (22 C) until used for experiments. All experiments in this study were carried out following the NIH Guidance for the Care and Use of Laboratory Animals. The Committee of Animals Research in Kyoto Prefectural University of Medicine also approved the experiments.
Fluorescent double-labeling immunocytochemistry
Under deep pentobarbital anesthesia, animals were perfused via the left cardiac ventricle with 150 ml 0.1 m phosphate buffer containing 4% paraformaldehyde. Frozen frontal sections (25 m thick) were made from the brain fixed with paraformaldehyde. Fluorescent double-labeling immunocytochemistry was carried out using monoclonal antibody P2l-1C against PrRP (50 g/ml) (7) and SOM (dilution 1:3000; Yanaihara Institute, Shizuoka, Japan). As the second antibody, rhodamine-conjugated antimouse IgG antibody for detection of PrRP and fluorescein isothiocyanateconjugated antirabbit IgG antibody for detection of SOM were used, respectively. Preincubation of the antibody P2l-1C with PrRP eliminated the immunoreactivity on the sections.
Immuno-electron microscopy
Animals were perfused with 150 ml 0.1 m phosphate buffer containing 5% acrorein. Serial frontal sections (30 m thick) were cut from tissue blocks of brains using a microslicer. The sections were processed by the avidin-biotin complex (ABC) immunocytochemical method using antibody against PrRP (P2l-1C) similar to the initial immunoreactive staining of double-labeling immunocytochemistry for ordinal light microscopy. After confirmation of the features of PrRP-like immunoreactivity by light microscopy, the sections were additionally fixed in chilled 1% OsO 4 solution for 1 h, dehydrated through a graded series of acetone, and embedded in Epon 812 mixture. Ultrathin sections were stained with uranyl acetate and lead acetate and examined with a JEM200CX electron microscope (JEOL, Tokyo, Japan).
Intracerebroventricular (icv) administration of PrRP31 into rats
Synthetic rat PrRP31 was prepared as described previously (8) . Rats were anesthetized by iv administration of pentobarbital at 50 mg/kg, and then set in a rat brain stereotaxic apparatus (Narishige, Tokyo, Japan). A stainless-steel guide cannula (AG-12; EICOM, Kyoto, Japan) was inserted into the third ventricle (AP: ϩ7.1 mm from the interaural line, L: 0 mm from the midline, H: ϩ2.0 mm from the interaural line). These operated rats were housed in individual cages and kept for at least 3 days for recuperation before use in the experiments. Ten microliters of PBS with or without PrRP31 was injected into the third ventricle through a microinjection cannula that was inserted into the guide cannula at a flow rate of 2.5 l/min.
Neuronal response of hypothalamic SOM neurons after icv administration of PrRP31
To clarify whether SOM-neurons were stimulated by PrRP, we examined the immediate early gene product, NGFI-A (synonyms of NGFI-A are Zif/268, ERG-1, or Krox24), after the icv administration of PrRP31. This gene encodes a DNA-binding transcriptional factor with zinc finger motifs and is used as a marker that is induced immediately in a stimulated cell. For example, light-stimulation induced NGFI-A expression in the SOM-neurons within the PerVN, which were stimulated from the retinal ganglion cells via the neurons within the suprachiasmatic nucleus (9) . One hour after icv injection of 10 nmol PrRP31 or PBS as described above, animals were perfused with 150 ml 0.1 m phosphate buffer containing 5% acrorein. Frozen frontal sections (25 m thick) were made. For double-labeling immunocytochemistry for ordinal light microscopy, NGFI-A-immunoreactivity was visualized by the ABC method using anti-NGFI-antibody (dilution 1:2000; Santa Cruz Biotechnology, Inc., Santa Cruz, CA), with 3,3'-diaminobenzidine, tetrahydrochloride (DAB) as chromogen. After this initial immunoreactive staining, sections were treated with 0.3% H 2 O 2 for 30 min to inactivate peroxidase in ABC, followed by incubation with anti-SOM antibody (dilution 1:3000; Yanaihara Institute) for 3 days at 4 C. After processing by the ABC method, chromogen benzidine dihydrochloride was used to reveal SOM in the cytoplasm (10) .
In situ hybridization
Animals were perfused via the left cardiac ventricle with 150 ml 0.1 m phosphate buffer containing 4% paraformaldehyde. Frozen frontal sections (25 m thick) of the brain were cut from each animal, and then processed for in situ hybridization according to the floating method as described previously (4, 9) . The antisense RNA probe for rat PrRP receptor mRNA and the rat SOM mRNA probe were synthesized from the coding region of rat hGR3/UHR-1 complementary DNA (1116 bp) and SOM complementary DNA (400 bp) inserted into the plasmid vector pBluescriptII (Stratagene, La Jolla, CA). Control sections hybridized with each sense RNA probe did not show any positive signals for PrRP mRNA. In the double-labeling study, both the digoxigenin-labeled hGR3/UHR-1 RNA probe and [
35 S]-CTP-labeled SOM RNA probe were simultaneously used for the in situ hybridization. After detection of hGR3/UHR-1 mRNA using alkaline-phosphatase with 4-nitroblue tetrazolium chloride and 5-bromo-4-chloro-3-indolyl phosphate, the same sections were dipped in emulsion (Ilford K5) and exposed for 4 days.
After development, silver grains due to [
35 S]-CTP-labeled SOM probe were detected in the same neurons (9) .
Assays of plasma GH after icv administration of PrRP31
The rats implanted with the guide cannula were anesthetized with pentobarbital as described above, and then their bilateral jugular veins were exposed. Before the icv injection of PrRP31, 600 l blood was withdrawn from the jugular vein and 20 U/ml heparin was immediately added. Blood samples were subsequently prepared at 10, 20, 30, 40, and 60 min after the icv injection. By centrifugation, plasma was separated from each blood sample, and then its GH concentration was determined using a RIA system (Amersham Pharmacia Biotech, Little Chalfont, UK).
Effects of GH-releasing hormone (GRH) on plasma GH after icv injection of PrRP
After anesthetizing with pentobarbital, the rats implanted with the guide cannula had the catheter inserted into the right jugular vein 1 day before icv injection of PrRP31. Before icv injection of PrRP31, 300 l blood was withdrawn from the catheter of each rat and 20 U/ml heparin was added immediately. Ten minutes after the PrRP31 injection, GRH (Peptide Laboratories, Minoh, Japan) at the dose of 5 g/kg dissolved in saline or saline alone was administrated to the rat through the catheter. The administration of GRH was performed between 1300 and 1600 h. Blood samples were subsequently prepared at 10, 20, 30, 40, and 60 min after the GRH administration. The blood was replaced each time with an equal volume of saline containing heparin. GH concentrations in plasma samples were determined as described above.
Effects of cysteamine and anticortistatin/SOM antibody on the inhibition of GH secretion by PrRP31
Cysteamine hydrochloride was obtained from Wako Pure Chemical Industries, Ltd. (Osaka, Japan). Monoclonal anticortistatin/SOM antibody (CIS-9) was raised against rat cortistatin-14 conjugated with bovine thyroglobulin using 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide as a coupling agent. The splenocytes of mice immunized with the cortistatin-14-bovine thyroglobulin conjugates were fused with mouse myeloma cells, P3X63Ag8-U1, as described previously (11) . Hybridoma cells producing a monoclonal antibody, CIS-9 (IgG1, ), were selected. The antibody was purified from ascites fluid with a protein A-immobilized column (IPA-300; Repligen, Cambridge, MA). In an enzyme immunoassay using CIS-9, binding of biotin-labeled rat cortistatin-14 to CIS-9 was inhibited by rat cortistatin-14, rat cortistatin-29, SOM-14, and SOM-28 with 50% inhibitory concentration values of 1.2, 0.9, 0.9, and 1.4 nm, respectively, indicating that CIS-9 fully cross-reacted with SOM-14 and SOM-28.
Cysteamine (300 mg/kg, sc) and CIS-9 (1 mg/rat, iv) were administered in rats 4 and 2 h before the GRH administration, respectively. The administration of GRH and PrRP31, preparation of plasma samples, and measurement of GH levels were performed in the same manner as described above.
Statistical analyses
Values were expressed as the means Ϯ sem. Differences between groups were analyzed by the two-tailed Student's t test. Aspin-Welch's test was used when population variances were not equal. Values of P Ͻ 0.05 were considered statistically significant.
Results

Immunocytochemical analysis of PrRP-terminals within the PerVN
PrRP-immunoreactive fibers and terminals were found predominantly in the PerVN of the hypothalamus. A large number of PrRP-immunoreactive nerve fibers were also detected around SOM-immunoreactive neuronal elements using double-labeling immunocytochemistry (Fig. 1A) . Immuno-electron microscopy revealed that PrRP-immunoreactive axons made synapses on nonimmunoreactive neuronal soma and dendrites (Fig. 1, B and C) .
Neuronal response to icv administration of PrRP and its receptor within the PerVN
To clarify the SOM neuronal response to PrRP, expression of NGFI-A was examined by immunocytochemistry using antibodies against NGFI-A and SOM. After icv administration of PrRP31, NGFI-A was detected in the nuclei of many neurons within the PerVN especially in the SOM neurons; 92% of SOM neurons revealed NGFI-A immunoreactivity ( Fig. 2A) . However, NGFI-A was never detected in the neurons of the hypothalamic PerVN of PBS-injected animals (Fig.  2B) . Double-labeling in situ hybridization, which detected both PrRP receptor mRNA and SOM mRNA simultaneously showed that PrRP receptor mRNA was located in 32% of neurons with SOM mRNA signals in the hypothalamic PerVN (Fig. 3) .
The effect of icv administration of PrRP31 on plasma GH levels
To determine whether PrRP can directly act on SOMneurons, we administrated PrRP31 into the third ventricle and then examined the change in plasma GH levels. As shown in Fig. 4 at 10 min after icv administration of PrRP, GH in the plasma was significantly decreased and this level was maintained for 40 min in which we examined GH at 20, 30, and 40 min after icv administration of PrRP compared with that in the animals administered PBS.
The effect of icv administration of PrRP31 on the plasma GH secretion induced by GRH
We measured plasma GH after iv injection of GRH. Plasma GH samples were examined at 10, 20, 30, 40, and 60 min after GRH injection and the peak was at 10 min (Fig.  5 ). In addition, we examined how PrRP influenced GH secretion induced by GRH. As a control of GRH injection on the plasma GH level, the plasma GH level was 37.5 Ϯ 15.8 ng/ml after icv injection of PBS followed by iv injection of saline (PBS plus saline); however, the plasma GH level was increased to 536.4 Ϯ 106.4 ng/ml after icv injection of PBS followed by iv injection of GRH (PBS plus GRH). The plasma GH levels elevated by GRH were inhibited by icv injection of PrRP in a dose-dependent manner. Plasma GH became 262.4 Ϯ 38.3 ng/ml at 10 min after 1 nmol PrRP injection (PrRP plus GRH), compared with (PBS plus GRH) and become 67.0 Ϯ 26.1 ng/ml at 10 min after a 50-nmol injection of PrRP (PrRP plus GRH), compared with that of PBS plus GRH.
Effect of pretreatment of cysteamine on GH secretion by PrRP31
We examined the effect of a SOM-depletor, cysteamine (12, 13, 14) . As shown in Fig. 6 , icv administration of PrRP31 at 5 nmol significantly reduced the elevated plasma GH levels at 10 min after the iv GRH administration; that is, the plasma GH levels of PBSϩGRH were 536.4 Ϯ 106.4 ng/ml, whereas those of PrRPϩGRH were 220.8 Ϯ 64.4 ng/ml (P Ͻ 0.05). However, pretreatment with 300 mg/kg cysteamine induced increases in plasma GH levels and evidently abolished the inhibitory effect of PrRP31, i.e. the plasma GH levels of Cys plus PBS plus GRH were 639.0 Ϯ 76.0 ng/ml, whereas those of Cys plus PrRP plus GRH were 569.1 Ϯ 62.2 ng/ml.
To confirm that SOM was involved in the inhibitory effect of PrRP31 on the GH secretion, we examined the effect of a monoclonal antibody that is capable of neutralizing the activity of SOM. As shown in Fig. 6 , pretreatment with the antibody (150 
FIG. 4.
Effects of icv administeration of PrRP31 on plasma GH levels in rats. After icv administration of PrRP31 at 50 nmol (F) or PBS alone (E), plasma samples were prepared from rats at the intervals indicated in the figure. The numbers of rats used for PrRP and PBS administration were 8 and 7, respectively. Each value of the GH concentration represents the mean Ϯ SEM. ‫,ء‬ P Ͻ 0.05; ‫,ءء‬ P Ͻ 0.01, comparing the PrRP31-injected group with the PBS-injected group. FIG. 5. The effect of PrRP31 on the plasma GH levels elevated by GRH in rats. After icv injection of PrRP, 5 g/kg GRH was iv injected into rats, and then plasma samples were prepared at the intervals indicated in the figure. E, PBS plus saline, icv injection of PBS followed by iv injection of saline; F, PBS plus GRH, icv injection of PBS followed by iv injection of GRH; OE, 0.1 nmol PrRP plus GRH, icv injection of 0.1 nmol PrRP31 followed by iv injection of GRH; f, 1 nmol PrRP plus GRH, icv injection of 1 nmol PrRP31 followed by iv injection of GRH; ϫ, 50 nmol PrRP plus GRH, icv injection of 50 nmol PrRP31 followed by iv injection of GRH. The numbers of rats used for these experiments were 7, 9, 11, 8, and 8, respectively. Each GH concentration value represents the mean Ϯ SEM.
FIG. 6. The effect of cysteamine and anticortistatin/SOM antibody on the inhibition of GH secretion by PrRP31 in rats. Rats pretreated with 300 mg/kg cysteamine or a monoclonal anticortistatin/SOM antibody (CIS9, 1 mg/rat), or nontreated rats were subjected to icv injection of PrRP (5 nmol) followed by iv injection of GRH (5 g/kg), and then their plasma samples were prepared 10 min after the GRH injection. PBS, icv injection of PBS alone followed by iv injection of GRH under the condition without cysteamine treatment; PrRP, icv injection of PrRP31 followed by iv injection of GRH under the condition without cysteamine treatment; CysϩPBS, icv injection of PBS alone followed by iv injection of GRH after cysteamine treatment; CysϩPrRP, icv injection of PrRP31 followed by iv injection of GRH after cysteamine treatment. CIS9 plus PBS, icv injection of PBS alone followed by iv injection of GRH after antibody treatment; CIS9 plus PrRP, icv injection of PrRP31 followed by GRH after antibody treatment. The numbers of rats used for these experiments were 9, 10, 7, 8, 7 and 8, respectively. Each GH concentration value represents the mean Ϯ SEM. ‫,ء‬ P Ͻ 0.05, when comparing the PrRP group with the PBS group. mg/kg) induced a marked increase in the plasma GH level and evidently abolished the inhibitory effect of PrRP31, i.e. the plasma GH levels of antibody (CIS9) plus PBS plus GRH were 1239.8 Ϯ 129.8 ng/ml, whereas those of CIS9 plus PrRP plus GRH were 1041.2 Ϯ 52.1 ng/ml. Considering these findings together with the observations using cysteamine, PrRP31 was suggested to have inhibitory effects on GH secretion through the promotion of SOM (and cortistatin) secretion in the hypothalamus.
Discussion
Immunocytochemical analysis of PrRP with respect to the morphological interaction of SOM-neurons in the PerVN
In the present study, we revealed the morphological correlation between PrRP and the SOM-neurons within the PerVN. In the hypothalamus, the most prominent innervation of PrRP-immunoreactive fibers was found in the PerVN. Double-labeling immunocytochemistry using antibodies against SOM and PrRP clearly revealed that PrRP-immunoreactive fibers surrounding the SOM-immunoreactive neuronal perikarya and processes by confocal microscopy. Moreover, immuno-electron microscopy using antibody against PrRP showed the nerve terminals with PrRP-immunoreactivity formed the synaptic contacts with nonimmunoreactive neuronal elements within the PerVN, a significant number of which may belong to the SOM-neurons. Therefore, within the PerVN, PrRP may play a role as a neuromodulator or a neurotransmitter. The icv administration of PrRP induced the expression of NGFI-A in the majority of SOM-neurons within the PerVN. These findings strongly suggested that such SOM-neurons within the PerVN could be stimulated by PrRP injected into the ventricle. Moreover, some SOM-neurons expressed PrRP receptor mRNA. These neurons might be directly innervated by PrRP-nerve fibers.
Physiological analysis of PrRP to inhibit GH release through direct stimulation of SOM neurons
Secondly, we showed physiological evidence that PrRP could regulate plasma GH levels by direct stimulation of SOM. The icv administration of PrRP induced a rapid decrease in plasma GH levels. High dose injection of PrRP almost completely inhibited the increase in plasma GH levels induced by iv injection of GRH. After cysteamine pretreatment, which depleted SOM or anticortistatin/SOM antibody, PrRP never depressed the plasma GH levels. These findings suggested that PrRP inhibited the plasma GH level via stimulation of SOM production or secretion into the portal vessel through the median eminence. As summarized by the immunocytochemical and physiological evidence, the following was suggested; PrRP could stimulate SOM-neurons within the PerVN, as a neuromodulator or neurotransmitter via synaptic contacts, to secrete SOM into the portal vessels and finally inhibit GH secretion from the anterior pituitary.
Additional suggestions for the function of PrRP
Hinuma et al. (1) discovered PrRP and reported that PrRP has an ability to release PRL from the anterior pituitary cells. Recently, PrRP was additionally reported to affect several hypothalamic hormones. For example PrRP stimulated oxytocin neurons and CRH neurons in the hypothalamus by directly innervation (15, 16) . The icv administration of PrRP increased the plasma level of oxytocin and the plasma level of ACTH due to stimulation of CRH. However, it was not clarified whether SOM-, CRH-, or oxytocin-neurons were stimulated by PrRP simultaneously or respectively in the different situations in intact rat brains. In addition, PrRP was reported to contribute to the endocrine or autonomic nervous systems (17) (18) (19) . The variety of the functional roles of PrRP remains to be fully elucidated.
